This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to evaluate the clinical response of Gleevec. The secondary objectives are to evaluate the inhibition of PDGF receptor as determined by immunohistochemistry; to evaluate cytokine profiles pre and post imatinib therapy; to evaluate the pharmacokinetic profile of imatinib in HIV patients; and to evaluate the mechanisms of primary and secondary resistance to imatinib therapy.
Showing the most recent 10 out of 642 publications